Join to access to all OVN content. Join for Free
Aspiring MSL Insights: Does Your Degree Make You Qualified?

Aspiring MSL Insights: Does Your Degree Make You Qualified?


Share This Article


Aspiring MSL Insights: Does Your Degree Make You Qualified?

Some Aspiring MSL’s are retail pharmacists or freshly minted PharmD’s. Others are either new PhD’s or PHD candidates. Are these viable launching points to land into an MSL role? That’s the topic of this Aspiring MSL Insight.

Michael Pietrack heads up the Medical Affairs Recruiting at Kaye/Bassman International and hosts of the Pharmaverse Podcast. He's been recruiting MSL’s since 2007 and happy to share my insights with you, so let’s break these down individually.

Retail Pharmacists – Sadly, your background is not what companies are looking for because they want a clinical pharmacist who is involved in prescribing decisions and rubbing elbows with the very doctors they will be calling on. So, if you’re a retail pharmacist, our recommendation is to transition to a major hospital where you would be dedicated to one disease state. Companies want specialists not generalists, and they hire people who are deeply connected with the right docs.

New Grads – You are well on your way to becoming an MSL, but you need to let your experience incubate for about 5 years. Your degree alone will not get you the MSL role because everyone your competing with has the same credentials, so it is the depth of your experience and the strength of your contacts that will help you get the job. As noted above, we would recommend Pharmacists to work in a clinical setting where they are designated to a single therapeutic area, and for PhD’s we would recommend being at a key research center or at a pathology lab at a hospital so that you will have leveragable connections.

And for the PhD candidates – You are way too early and should apply all the advice already mentioned.

So, if you’re launching point is too far away from the landing point, maybe there is a closer launching point that you need to hit first. This video is not to discourage you, but to inform you so that you can position yourself to get that MSL job you are dreaming about. So, don’t give up. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
OVN Avatar The Oncology Nursing Podcast

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Explore OVN